Kite Pharma Expands Cooperation Agreement With Sourasky

January 25, 2015 | The Israeli biopharmaceutical company Kite Pharma announced that it has expanded on its agreement with Tel Aviv’s Sourasky Medical Center that will help it research and develop its CAR T technology. CAR T is a cellular therapy that is used as part of Kite Pharma’s cancer immunotherapy treatments. As part of the agreement, Kite Pharma will partner with Prof. Zelig Eshhar, an expert in CAR T research and the Chair of Immunology Research at Sourasky. Kite Pharma was founded in 2009 and is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system’s ability to recognize and eradicate tumors.